Vyzulta (latanoprostene bunod) / Bausch Health, Nicox - LARVOL DELTA

Corrigendum: Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. (PubMed, Med Gas Res) - No abstract available

Journal • Glaucoma • Ophthalmology

Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review. (PubMed, Front Ophthalmol (Lausanne)) - "LBN was generally well tolerated in real-world studies; the most common adverse events were consistent with the known safety profile of LBN. Data from real-world studies provide important insights regarding the potential effectiveness and tolerability of LBN in the clinical setting and suggest that LBN is well tolerated and associated with significant, clinically meaningful, and durable reductions in IOP."

Journal • Real-world evidence • Review • Cardiovascular • Glaucoma • Ophthalmology

Impact on intraocular pressure after switching to Latanoprostene Bunod in patients with glaucoma in real-world clinical practice (ARVO 2025) - "These large-scale real-world study findings are consistent with those observed in smaller observational studies and clinical trials, confirming LBN effectiveness in real-world clinical practice Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Real-world • Real-world evidence • Glaucoma • Ophthalmology

Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. (PubMed, Med Gas Res) - "Latanoprostene bunod has demonstrated strong efficacy and a favorable safety profile in both clinical trials and real-world studies. Given the promising results of latanoprostene bunod and advancements in drug delivery, topical fixed-combination and sustained-release formulations containing latanoprostene bunod and other agents targeting different intraocular pressure-lowering mechanisms may become available in the future."

Journal • Review • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Effects of 0.024% latanoprostene bunod on intraocular pressure and pupil diameter in normal cats and cats with congenital glaucoma. (PubMed, Vet Ophthalmol) - "Transient IOP reduction was observed after topical administration of LAT and LBN in FCG cats; and mean IOP difference was statistically significantly greater in LBN-treated eyes. However, the apparent enhanced hypotensive effect of LBN is not clinically significant."

Journal • Glaucoma • Ophthalmology

The Effect of Latanoprostene Bunod 0.024% on Optical Coherence Tomography Angiography in Newly Diagnosed Open Angle Glaucoma. (PubMed, J Glaucoma) - "In conclusion, treatment with LBN ophthalmic solution 0.024% reduced IOP by an average of 29.9% and 31.8% in patients with POAG and PXG, respectively, and improved VD in different quadrants in all slabs. Therefore, the importance of LBN in the treatment of glaucoma is likely to be that it increases macular microcirculation, possibly via NO, independent of its IOP-reducing effect."

Journal • Glaucoma • Ophthalmology

Reduction in IOP After Switching to Latanoprostene Bunod in Glaucoma Patients in Real-World Clinical Practice (AAO 2024) - "IOP reductions were statistically significant. Conclusion Overall, 33%-46% patients had an IOP reduction of ≥20% after switching to LBN in real-world clinical practice, supporting the effectiveness of LBN therapy."

Clinical • Real-world • Real-world evidence • Glaucoma • Ophthalmology

One-year experience with latanoprostene bunod ophthalmic solution 0.024% in clinical practice: A retrospective observational study. (PubMed, PLoS One) - "Although high intolerable adverse effects including conjunctival hyperemia and eye irritation happened in the first month, remaining sixty percent of patients exhibited statistically significant additional IOP reductions in the replacement of other PGAs during 12 months of clinical use of LBN 0.024%."

Journal • Observational data • Retrospective data • Glaucoma • Ophthalmology

Effect Of Latanoprostene Bunod Ophthalmic Solution On Peripapillary And Macular Density (ESCRS 2024) - No abstract available

Ophthalmology

The comparative effectiveness of latanoprostene and latanoprost in lowering IOP in young guinea pigs, a common myopia model. (ARVO 2024) - "The IOPs (iCare tonometer), cycloplegic refractions (1% cyclopentolate; spherical equivalent refractive errors, SERs), and axial lengths (ALs; Lenstar optical biometer (Haag-Streit) measurements were collected before treatment initiation and weekly thereafter, all at approximately same time of day. The observed reductions in IOP in young guinea pigs treated with both latanoprostene and latanoprost, as opposed to artificial tears, and the slightly greater effect of the former support the further investigation of latanoprostene, specifically its ability to slow progression in a guinea pig myopia model. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details.: Myopia, commonly known as near-sightedness, manifests as a discrepancy between the eye's refractive power and its axial length, culminating in the..."

HEOR • Glaucoma • Ophthalmology

Intraocular Pressure Reduction Treatment through a Sustained-Release System Loaded with LBN in a Novel Nanoscale Zinc/Iron Mixed-Metal MOF-74 (ARVO 2024) - "We designed Zinc/Iron Mixed-Metal MOF-74 to load the nitric oxide analog Latanoprostene Bunod (LBN), a prostaglandin F2α analog to explore a safe and effective nano-material for delivering LBN with sustained release... The newly developed nano-material represents a promising avenue for reducing intraocular pressure in glaucoma treatment. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details.: We have developed a nano-material that carries the intraocular pressure-lowering drug LBN."

Glaucoma • Ophthalmology

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Bausch & Lomb Incorporated | N=34 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology

Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review. (PubMed, Clin Ophthalmol) - "Of 14 ocular AEs, 3 were recorded as such (mild in severity, considered unrelated to treatment), and 11 were identified through review of interval ocular histories (no severity/relatedness information); none led to discontinuation. In this short-term retrospective chart review of mild-to-moderate OAG/OHT, switching prior IOP-lowering therapy to LBN produced an additional ~25% IOP reduction and appeared to be well tolerated."

Journal • Retrospective data • Review • Cardiovascular • Glaucoma • Ophthalmology

NON-INVASIVE EVALUATION OF MEIBOMIAN GLAND MORPHOLOGY AND TEAR FILM AND ANTERIOR SEGMENT PARAMETERS IN TOPICAL LATANOPROST AND LATANOPROSTENE BUNOD USERS FOR OPEN-ANGLE GLAUCOMA MEDICATION (ESCRS-WM 2024) - No abstract available

Glaucoma • Ophthalmology

Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024. (PubMed, J Curr Glaucoma Pract) - "Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024%. J Curr Glaucoma Pract 2023;17(4):205-209."

Journal • Glaucoma • Ophthalmology

Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review. (PubMed, Curr Opin Pharmacol) - "Emergent PGAs, such as latanoprostene bunod, fixed-dose netarsudil combined with latanoprost, and omidenepag Isopropyl, offer enhanced or non-inferior IOP reduction. The bimatoprost implant introduces a novel administration method with effective IOP reduction. These developments underscore ongoing progress in PGA-focused ophthalmological research. This article offers a comprehensive review of available prostanoid analogs and explores new developments."

Journal • Review • Cardiovascular • Glaucoma • Ophthalmology

Difficult decisions, filtration surgery, and the heartbreak of the numerator. (PubMed, J Cataract Refract Surg) - "He was intolerant to dorzolamide, brimonidine, and netarsudil...Medications included timolol and latanoprostene bunod in the right eye only...An extensive discussion ensued about the best course of action for the right eye. How would you proceed in managing definite progression in this individual's right eye, knowing that he had lost fixation in his left eye at similar pressures?"

Journal • Surgery • Glaucoma • Hematological Disorders • Ophthalmology

Serous Retinal Detachment in a Patient With a Port-Wine Birthmark Associated With Prostaglandin Analog Therapy. (PubMed, Ophthalmic Surg Lasers Imaging Retina) - "An 11-year-old girl with a port-wine birthmark (PWB), diffuse choroid hemangioma (DCH), and glaucoma experienced decreased vision upon starting treatment with bimatoprost. The patient was switched to latanoprostene bunod...This report highlights the importance of regular surveillance for SRD in patients with DCH who are receiving PGA. [Ophthalmic Surg Lasers Imaging Retina 2023;54:723-729.]."

Journal • Achromatopsia • Glaucoma • Ophthalmology • Retinal Disorders

Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review. (PubMed, Expert Opin Investig Drugs) - "Three novel drugs targeting FP receptors were identified, including latanoprostene bunod, NCX 470, and sepetaprost. Alternatively, drug delivery systems may provide a similar IOP lowering effect to existing agonists but overcome issues with patient compliance and convenience. A personalized approach to drug delivery devices may be required to ensure the most appropriate fit for the patient according to the invasiveness and duration of therapy desired."

Journal • Review • Cardiovascular • Glaucoma • Ophthalmology

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity (clinicaltrials.gov) - P=N/A | N=70 | Completed | Sponsor: University of California, San Diego | Trial completion date: May 2021 ➔ Mar 2023

Trial completion date • Cardiovascular • Glaucoma • Ophthalmology

Emerging glaucoma treatments: are we seeing an improvement in adherence? (PubMed, Expert Rev Ophthalmol) - "Offering personalized patient education and coaching to support chronic glaucoma self-management would better enable patient engagement in whichever treatment path is chosen. Currently, literature regarding the impact of these new advancements on treatment engagement is lacking; this field is ripe for additional intervention and assessment."

Adherence • Journal • Glaucoma • Ophthalmology

Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients. (PubMed, Pharmaceuticals (Basel)) - "A unique nitric oxide-donating conjugate of latanoprost, an FP-receptor prostaglandin (PG; latanoprostene bunod), new rho kinase inhibitors (ripasudil; netarsudil), a novel non-PG EP2-receptor-selective agonist (omidenepag isopropyl), and a form of FP-receptor PG in a slow-release intracameral implant (Durysta) represent the additions to the pharmaceutical toolchest to mitigate the ravages of OHT. Despite these advances, early diagnosis of OHT and glaucoma still lags behind and would benefit from further concerted effort and attention."

Journal • Review • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Systematic review of clinical practice guidelines for the diagnosis and management of open angle glaucoma (SOE 2023) - "NICE, SNS and IETSI CPGs for the diagnosis and management of OAG have a high methodological quality, appraised with AGREE-II. _x000D_ _x000D_ _x000D_"

Clinical • Clinical guideline • Review • Glaucoma • Ophthalmology

Latanoprostene bunod 0.024% in patients switched from prior pharmacotherapy: A multicenter retrospective chart review (AOA 2023) - No abstract available

Retrospective data • Review • Ophthalmology

Effects of diurnal fluctuation and chronic pressure-lowering eye drops on intraocular pressure (IOP) in a mouse model of glaucoma (ARVO 2023) - "Animals were then given daily topical therapy with either latanaprost (LA) or latanoprostene bunod (LBN) for two weeks; drops were given at around 8am, soon after dark onset, and IOP was measured up to 7hrs afterwards...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Preclinical • Glaucoma • Ophthalmology